Articles By Anuja Singh
Can Roche’s 2025 Launches and Approvals Reinforce Its Leadership in Oncology, Diagnostics, and Neuroscience…
Global | January 2026 — Roche Holding AG achieved a strong year in 2025, marked by multiple regulatory…
ByCan Novartis’ 2025 Approvals and Launches Strengthen Its Position Across Oncology, Neuroscience, and Rare…
Global | January 2026 — Novartis AG advanced its strategic portfolio in 2025 with multiple product approvals and…
Can Johnson & Johnson’s 2025 Product Momentum and Portfolio Execution Sustain Leadership Across Oncology,…
Global | January 2026 — Johnson & Johnson continued to reinforce its position as one of the world’s…
Can Gilead’s 2025 Approvals and Targeted Launches Reinforce Leadership in HIV, Oncology, and Liver…
Global | January 2026 — Gilead Sciences, Inc. strengthened its innovation-led growth profile in 2025 through a focused…
Can AbbVie’s 2025 Launches and Portfolio Expansion Offset Post-Humira Transition and Drive Sustainable Growth…
Global | January 2026 — AbbVie Inc. accelerated its post-Humira transformation in 2025, advancing a diversified portfolio across…
Can Merck’s 2025 Launches, Label Expansions, and Oncology Leadership Sustain Growth Momentum Into 2026…
Global | January 2026 — Merck & Co., Inc. (MSD outside the U.S. and Canada) reinforced its position…
Can Roche’s 2025 Launches and Approvals Reinforce Its Leadership in Oncology, Diagnostics, and Neuroscience…
Global | January 2026 — Roche Holding AG achieved a strong year in 2025, marked by multiple regulatory…
Can Novartis’ 2025 Approvals and Launches Strengthen Its Position Across Oncology, Neuroscience, and Rare…
Global | January 2026 — Novartis AG advanced its strategic portfolio in 2025 with multiple product approvals and…
Can Johnson & Johnson’s 2025 Product Momentum and Portfolio Execution Sustain Leadership Across Oncology,…
Global | January 2026 — Johnson & Johnson continued to reinforce its position as one of the world’s…
Can Gilead’s 2025 Approvals and Targeted Launches Reinforce Leadership in HIV, Oncology, and Liver…
Global | January 2026 — Gilead Sciences, Inc. strengthened its innovation-led growth profile in 2025 through a focused…
Can AbbVie’s 2025 Launches and Portfolio Expansion Offset Post-Humira Transition and Drive Sustainable Growth…
Global | January 2026 — AbbVie Inc. accelerated its post-Humira transformation in 2025, advancing a diversified portfolio across…
Can Merck’s 2025 Launches, Label Expansions, and Oncology Leadership Sustain Growth Momentum Into 2026…
Global | January 2026 — Merck & Co., Inc. (MSD outside the U.S. and Canada) reinforced its position…